美多芭联合吡贝地尔治疗帕金森病的临床疗效及安全性

Clinical effect and safety of medopa combined with piribedil in the treatment of parkinson disease

目的探讨美多芭联合吡贝地尔治疗帕金森病(PD)的临床疗效及安全性。方法选取南充市中心医院2012年6月—2013年12月收治的PD患者47例,随机分为对照组23例和联合组24例。对照组患者给予美多芭治疗,联合组患者在对照组基础上给予吡贝地尔治疗,两组患者均持续治疗48个月。比较两组患者的临床疗效,治疗前、治疗12、24、36、48个月时帕金森氏病综合评分量表(UPDRS)评分及治疗期间药物不良反应发生情况。结果联合组患者临床疗效优于对照组(P<0.05)。治疗前及治疗12个月,两组患者UPDRS评分比较,差异无统计学意义(P>0.05);治疗后24、36、48个月时,联合组患者UPDRS评分低于对照组(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论美多芭联合吡贝地尔治疗PD的临床疗效确切,可有效降低UPDRS评分,改善患者症状,安全性好。

Objective To discuss the clinical effect and safety of medopa combined with piribedil in the treatment of parkinson disease （PD）. Methods A total of 47 PD patients were selected from June 2012 to December 2013 in Nanchong Central Hospital, which were divided into control group （n = 23 ） and combination group （n = 24）. The control group was treated with medopa, combination group was treated with piribedil on the basis of control group, both groups were treated for 48 months. The clinical effect, UPDRS scores before treatment and after treatment of 12, 24, 36, 48 months, and the incidence of adverse reactions were compared between the two groups. Results The clinical effect of combination group was better than control group （P 〈 0. 05）. Before treatment and after treatment of 12 months, no significant differences of UPDRS scores was found between the two groups （ P 〉 0. 05 ） ; after treatment of 24, 36, 48 months, the UPDRS scores of combination group were lower than control group （P 〈 0. 05 ）. There was no significant difference of adverse reactions rate between the two groups （ P 〉 0. 05）. Conclusion Medopa combined with piribedil have an obviously clinical effect in the treatment of PD, it can lower UPDRS scores, improve the symptoms, and with good safety.